Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline
- Dr Martin brings over two decades of leadership in translational science, drug discovery and biotech strategy and entrepreneurship
- Strengthens Link’s position as it advances its proprietary TSG-6-based therapeutic pipeline towards the clinic
London, UK – 24 February 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies, that have a unique combination of anti-inflammatory, tissue-protective and tissue-reparative properties, today announces the appointment of Dr Niall Martin, PhD, FMedSci, to its Board of Directors. This strategic appointment marks a defining step in the Company’s growth as it accelerates its TSG-6-based therapeutic pipeline towards the clinic.
